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The prevalence and trends of pulmonary nontubercu-
lous mycobacteria (NTM)–associated hospitalizations in the 
United States were estimated using national hospital dis-
charge data. Records were extracted for all persons with 
a pulmonary NTM International Classification of Diseases 
code (031.0) hospitalized in the 11 states with continuous 
data available  from 1998 through 2005. Prevalence  was 
calculated using US census data. Pulmonary NTM hospital-
izations (031.0) increased significantly with age among both 
sexes: relative prevalence for persons 70–79 years of age 
compared with those 40–49 years of age was 15/100,000 
for women (9.4 vs. 0.6) and 9/100,000 for men (7.6 vs. 0.83). 
Annual prevalence increased significantly among men and 
women in Florida (3.2%/year and 6.5%/year, respectively) 
and among women in New York (4.6%/year) with no sig-
nificant changes in California. The prevalence of pulmonary 
NTM–associated hospitalizations is increasing in selected 
geographic areas of the United States. 
C
linic-  and  laboratory-based  studies  since  the  1980s 
have shown an increased prevalence of persons with 
nontuberculous mycobacterial (NTM) pulmonary disease 
(1,2) with a predominance of women >60 years of age who 
have no underlying risk factors (3–5). NTM comprise a 
multispecies group of environmental organisms living in 
soil as well as in treated and untreated water sources. These 
mycobacteria were first identified as human pathogens in 
the 1950s when 1%–2% of patients in tuberculosis (TB) 
sanitaria did not respond to traditional TB treatment. Their 
illnesses were caused by organisms that were not Mycobac-
terium tuberculosis. These patients tended to be older than 
those having TB, were more likely to be white, and to have 
underlying lung disease (6,7).
The success of TB elimination efforts has resulted in 
a continued decline in the incidence and prevalence of tu-
berculosis in the United States. In 2007, the incidence of 
TB in the United States was 4.4/100,000 population, and 
2.1/100,000 among US-born persons, the lowest rates since 
reporting began in 1953 (8). The apparent increase in NTM 
disease has occurred during the same period that TB has 
been declining. Although NTM are not transmissible, the 
diseases they cause may greatly affect public health and 
medical care resources. In some state health departments, 
findings of an acid-fast bacilli, indicative of mycobacteria, 
are reportable (9), and may trigger a public health investi-
gation with substantial expenditure of resources until spe-
cies identification is confirmed.
Population-based  surveys  conducted  during  1981–
1983 estimated the prevalence of pulmonary NTM dis-
ease at 1–2 cases/100,000 persons in the United States 
(10). A more recent retrospective analysis from Ontario, 
Canada found an average annual increase of 8.4% for the 
isolation prevalence of NTM at the Ministry of Health 
Mycobacterial Laboratory between 1997 and 2003 (11). 
Similar trends have been noted in other areas of the world 
(12–16). However, no current US nationally representa-
tive data exist regarding the prevalence of pulmonary dis-
ease associated with NTM. Furthermore, information is 
limited regarding risk factors associated with the disease. 
Our study describes the prevalence, demographic charac-
teristics, and trends of pulmonary NTM–associated hospi-
talizations during 1998–2005.
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Methods
Data Source and Study Population
We  used  data  from  the  Agency  for  Healthcare  Re-
search and Quality’s Healthcare Cost and Utilization Proj-
ect  (HCUP),  specifically  the  State  Inpatient  Databases 
(SID). The SIDs provide record-level data, without per-
sonal identifiers, on nearly 100% of community hospital 
discharges in participating states. Records were included 
for hospitalizations that had an International Classification 
of Diseases, 9th Revision, Clinical Modification (ICD-9-
CM), code associated with pulmonary NTM (031.0) as a 
primary or secondary discharge diagnosis. The study pop-
ulation included all records for persons hospitalized with 
pulmonary NTM as a primary or secondary diagnosis in 
the 11 states participating in HCUP (Arizona, California, 
Colorado, Florida, Illinois, Iowa, Massachusetts, New Jer-
sey, New York, Washington, and Wisconsin) during the 
years specified (17). These states represented 42% of the 
US population during the study period.
Data Analysis
Data elements available in the HCUP dataset included 
year of hospitalization, age when hospitalized, sex, state 
where  hospitalization  occurred,  type  of  NTM  infection 
(pulmonary, disseminated, cutaneous, unspecified, or oth-
er) and up to 29 possible secondary diagnoses. No informa-
tion on mycobacterial species is available in this dataset. 
Because  NTM  is  known  to  be  a  common  opportunistic 
infection  among  people  with  AIDS,  particularly  before 
the widespread availability of combination antiretroviral 
medications  (18),  we  limited  our  analysis  to  non-AIDS 
NTM using the code for HIV/AIDS (042), which indicates 
hospitalizations where AIDS was known to be an underly-
ing illness. Additionally, we restricted our analysis to the 
1998–2005 study period to avoid misclassification among 
types of NTM because the ICD-9-CM code for dissemi-
nated NTM was introduced in 1997. Before implementa-
tion, hospitalizations associated with disseminated NTM 
may have been included in the 4 other NTM categories 
(pulmonary, cutaneous, unspecified, other). We examined 
prevalence trends in pulmonary NTM by age and sex and 
described  the  most  frequently  associated  underlying  ill-
nesses. To analyze the most frequent secondary underly-
ing illnesses, we grouped the following conditions/codes as 
chronic obstructive pulmonary disease (COPD): obstructive 
chronic bronchitis with and without exacerbation (ICD-9-
CM 491.21, 491.22); emphysema not elsewhere classified 
(492.8); chronic obstructive asthma (493.20); and chronic 
airway obstruction not elsewhere classified (496).
To  estimate  prevalence  of  hospitalizations,  we  used 
age- and sex-specific US census data for participating states 
during the study period; both individual years and midpoint 
population (average of 2001–2002 census population esti-
mates) were used as appropriate. Although prevalence more 
often refers to the number of persons with a condition in a 
population at a determined time, we use it here to describe 
the number of hospitalizations among persons with NTM. 
To compare prevalence among states, we calculated age-
and sex-adjusted rates using the US census 2000 reference 
population;  χ2  tests  were  used  to  determine  significance 
among groups at a significance level of p<0.05. Data analy-
ses were calculated using SAS 8.0 and 9.1 (SAS, Cary, NC, 
USA) and EpiInfo version 3.4 (Centers for Disease Con-
trol and Prevention, Atlanta, GA, USA). The average an-
nual percent increase in prevalence and the significance of 
these trends were estimated by use of Poisson regression 
models. Prevalence was modeled as a function of time, with 
prevalence as the dependent variable and time as the inde-
pendent variable; Pearson’s scale factor was used to account 
for overdispersion. Model fit was assessed by the value of 
the scaled Pearson χ2, which equals the value divided by the 
degrees of freedom (value/DF); a value of 1 indicates that 
the model is a good fit. Wald 95% confidence limits were 
estimated as well. For modeling trends by age and sex for 
all 11 states combined, separate models were fit for each 
age and sex group. Prevalence was defined as the number of 
observed cases in a given age and sex group for each year 
as the numerator and the estimated annual population for 
the specified age and sex group for that year as a denomina-
tor, modeled in SAS as the observed count data with a log 
population offset. For estimation of average annual percent 
change for men and women in 3 states (California, Florida, 
and New York), age-adjusted prevalence was the dependent 
variable, modeled as expected number of cases with a log 
population offset; time (year) was the independent variable. 
Models were fit separately for men and women. A constant 
term was included as part of these equations.
Results
From 1998 through 2005, a total of 23,216 pulmonary 
NTM–associated hospitalizations were identified, of which 
16,475  (71%)  were  non-AIDS  related.  Of  these,  9,439 
(57%) were women and 8,997 (55%) were among persons 
>70 years of age. The proportion of pulmonary NTM hos-
pitalizations among persons >70 years of age varied by sex: 
45% of men and 62% of women were >70 years of age. 
For both sexes, the average annual prevalence of non-AIDS 
pulmonary NTM-associated hospitalizations increased with 
age, but among persons >70 years of age, the relative prev-
alence was higher for women than for men. The relative 
prevalence for persons 70–79 years of age compared with 
those 40–49 years of age was 15-fold higher for women 
(9.4/100,000 vs. 0.6/100,000), and 9-fold higher for men 
(7.6/100,000 vs. 0.8/100,000); similar relative differences 
were seen in the >80–95-year age group (Figure 1).
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To study trends within the older age groups over time, 
we restricted our analysis to the >50-year age group and 
examined trends during the period 1998–2005 for men and 
women separately. Among men, the prevalence decreased 
significantly among the 50–59-year age group (2.7% per 
year; p = 0.011 by χ2 test), and increased significantly among 
men 70–79 years of age (5.3% per year; p = 0.0001 by χ2 
test); no significant changes were evident in the other age 
groups (Table 1; Figure 2). Among women, the prevalence 
increased significantly for women 60–79 years of age with 
an average annual increase of 4.6% (p = 0.0069 by χ2 test) 
among women 60–69 years of age and 5.5% (p<0.0001) 
among women 70–79 years of age (Table 1; Figure 3).
We studied trends by geographic area and chose the 
3 states with the greatest numbers of annual observations 
during the study period to ensure robust trend analysis. Cal-
ifornia, Florida, and New York represent unique regions 
in the United States and overall comprised 62% of NTM 
hospitalizations in the 11 states included in the analysis. 
To compare prevalence across these states, we calculated 
age-adjusted prevalence for men and women. Among both 
sexes, prevalence was highest in Florida; a significant an-
nual increase was seen from 1998 through 2005. Among 
men, the average annual age-adjusted prevalence in Florida 
was  2.1/100,000  population,  with  a  significant  increase 
from 2.1 to 2.4 (3.2% increase/year); the average annual 
prevalence in California was 1.3 and for New York 1.4, 
with no significant change during the study period (Table 1, 
Figure 4). Among women, the average annual age-adjusted 
prevalence in Florida was 2.4/100,000; an increase of 1.8 
in 1998 to 2.8 in 2005 (average 6.5%/year) was identified. 
For women in New York, annual prevalence increased sig-
nificantly  from  1.4/100,000  to  1.9/100,000  (4.6%/year); 
no significant change was detected in California (Table 1; 
Figure 5.)
Among the 16,475 non-AIDS pulmonary NTM–asso-
ciated hospitalizations during 1998–2005, a total of 5,148 
(31%) hospitalizations had pulmonary NTM as a primary 
diagnosis. The other leading primary diagnoses were pneu-
monia (7%), obstructive chronic bronchitis with acute ex-
acerbation (5%), acute respiratory failure (2%), congestive 
heart failure (1.4%), and bronchiectasis (1.3%). No other 
single primary diagnosis comprised >1% of the primary 
diagnosis (Table 2). We analyzed secondary diagnoses to 
identify associated underlying illnesses for hospitalizations 
where pulmonary NTM was the primary diagnosis. Hospi-
talizations could be associated with combinations of up to 
















































Figure  1.  Average  annual  prevalence  of  non-AIDS  pulmonary 
nontuberculous  mycobacteria–associated  hospitalizations  by 
age group and sex, Healthcare Cost and Utilization Project state 
inpatient databases, USA, 1998–2005.
Table 1. Results of Poisson regression modeling for trends in 
pulmonary NTM, HCUP-SID, USA, 1998–2005* 
Group  Sex 
Annual % 
change  Wald 95% CI p value 
State         
  California  M  –1.5  –4.0–1.3  0.24 
   F  –1.5  –3.3–0.3  0.10 
  New York  M  –2.7  –5.9–0.54  0.10 
   F  4.5  1.1–8.2  0.0097 
  Florida  M  3.2  0.76–5.7  0.010 
   F  6.3  3.1–9.9  0.00010 
Age group, y         
  50–59  M  –2.7  –4.8 to –0.61 0.0118 
   F  0.14  –1.4–1.7  0.8629 
  60–69  M  –1.5  –3.1–0.01  0.0490 
   F  4.6  1.2–8.0  0.0069 
  70–79  M  5.3  2.5–8.2  0.0001 
   F  5.5  2.9–8.2  <0.0001 
  >80  M  0.65  –3.0–4.4  0.7327 
   F  2.5  –0.62–5.7  0.1177 
*NTM, nontuberculous mycobacteria; HCUP, Healthcare Cost and 
Utilization Project; SID, state inpatient databases; CI, confidence interval. 
The scaled Pearson Ȥ
2 (value/df) was 1 for all items. 
Figure  2.  Prevalence  of  non-AIDS  pulmonary  nontuberculous 
mycobacteria–associated  hospitalizations  among  men  by  age 
group and year, Healthcare Cost and Utilization Project (HCUP) 
state inpatient databases, USA, 1998–2005.Nontuberculous Mycobacteria Lung Disease, USA
29 secondary diagnoses, such that the sum of the underly-
ing illnesses identified in any of those fields could add up 
to >100%. Of these, preexisting cardiovascular conditions, 
such as hypertension and atrial fibrillation, were most com-
mon (47%). Structural lung diseases, such as COPD (34%) 
and bronchiectasis (15%), were also common (Table 3).
To  identify  distinct  patterns  of  underlying  illnesses 
by sex, we analyzed the age and sex distribution for se-
lected underlying illnesses among hospitalizations where 
non-AIDS pulmonary NTM was the primary diagnosis. For 
hospitalizations with secondary diagnoses related to COPD, 
the prevalence of hospitalization was higher for men than 
for women in all age groups, ranging from 2-fold in the 
50–59-year age group, to 1.3× greater in the >70-year age 
group (Figure 6). Among persons hospitalized with bron-
chiectasis  as  a  secondary  diagnosis,  the  prevalence  was 
consistently higher in women than in men in all age groups, 
ranging from 3-fold higher in the 50–59-year age group to 
4-fold in the 70–79-year age group (Figure 7).
Discussion
We  present  nationally  representative  population-
based prevalence estimates for pulmonary NTM disease, 
age-specific  prevalence  estimates  for  the  United  States, 
and prevalence data available on hospitalizations associ-
ated with pulmonary NTM disease. Estimates of this type 
were reported in 1987 (10). In addition, we demonstrate an 
increasing prevalence of pulmonary NTM-associated hos-
pitalizations among both men and women in Florida, dif-
ferent than that for California and New York, and identify 
regional differences in disease activity as has been previ-
ously suggested (19).
The increased prevalence among those >50 years of age 
indicates a disease process with onset in the fifth or sixth 
decade of life, either as a result of an underlying genetic 
susceptibility or onset of underlying illnesses (e.g., COPD). 
Although our data are derived from hospitalizations associ-
ated with NTM rather than outpatient visits, which might 
be more likely to occur earlier in the disease course, data 
from outpatient settings show a similarly increased disease 
effect in the >50 year-old population (1,3,5). Because prev-
alence is a function of disease incidence and duration, the 
highest prevalence in the oldest age groups likely reflects 
new cases as well as the accumulation of existing cases, 
i.e., persons living with the disease. For this reason we can-
not draw more specific conclusions regarding age at onset 
of illness.
Among persons >70 years of age, the higher age-spe-
cific prevalence of women relative to men is consistent with 
prior single site studies showing a predominance of pulmo-
nary NTM diagnosed in women (1,3–5), an apparent change 
from the 1970s and 1980s when men predominated among 
cases of pulmonary NTM (10). Although women aged >70 
years have an increased prevalence relative to men in the 
same age group, the effect among men is still substantial. 
NTM in women may predominate in more recent clinical 
studies because women outnumber men in the older age 
groups; when number of cases relative to their represen-
tation in the population are considered (e.g., age-specific 
disease prevalence), the sex differences are reduced.
The absence of a predominant co-illness is notewor-
thy, especially in this hospitalized population, and supports 
the possibility of diverse etiologies for NTM disease. Other 
than pulmonary NTM, no single diagnosis comprised more 
than 7% of primary diagnoses. This finding is consistent 
with  observations  from  recent  single-site  studies  of  an 
increasing proportion of cases having no known risk fac-
tors, particularly among women (1,3–5). Bronchiectasis, a 
defining feature for NTM disease (20), was identified and 
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Table 2. Primary diagnoses, non-AIDS pulmonary NTM-
associated hospitalizations, HCUP-SID, USA, 1998–2005* 
ICD-9 code  Primary diagnosis  No. (%) 
0310 Pulmonary NTM  5,148 (31.25) 
482 Pneumonia 1,156 (7.01) 
49121 Obstructive chronic bronchitis 
with acute exacerbation 
821 (4.98) 
51881 Acute respiratory failure  392 (2.38) 
4280 Congestive heart failure, 
unspecified
225 (1.37) 
4941 Bronchiectasis with acute 
exacerbation 
216 (1.31) 
2765 Volume depletion  196 (1.19) 
515 Postinflammatory pulmonary 
fibrosis
186 (1.13) 
5070 Aspiration pneumonia caused by 
inhalation of food/vomitus 
176 (1.07) 
Other primary diagnosis <1% of 
population
7,959 (48.3) 
*NTM, nontuberculous mycobacteria; HCUP, Healthcare Cost and 
Utilization Project; SID, state inpatient databases; ICD-9, International 
Statistical Classification of Diseases, Revision 9. 
Figure  3.  Prevalence  of  non-AIDS  pulmonary  nontuberculous 
mycobacteria–associated hospitalizations among women by age 
group and year, Healthcare Cost and Utilization Project (HCUP) 
state inpatient databases, USA, 1998–2005.RESEARCH
coded as the primary diagnosis in only 1.3% of hospital-
izations caused by NTM. Among discharged patients for 
whom pulmonary NTM was the primary diagnosis, 15% 
had bronchiectasis listed as a secondary diagnosis. Because 
the criteria for defining NTM disease include bronchiecta-
sis, we suspect that a higher proportion of patients than 
were reported actually had this condition.
The reasons for the low proportion are unclear, but may 
reflect the relative difficulty of diagnosing bronchiectasis 
without a computed tomography scan. In this same group 
having NTM as a primary discharge diagnosis, 47% had 
cardiac conditions and 33% had COPD/emphysema. The 
more frequent diagnosis of COPD among men having pul-
monary NTM and of bronchiectasis among women with pul-
monary NTM is consistent with previous studies (3,21,22). 
Although some of this difference in disease presentation 
could be related to a gender diagnostic bias (23), it may 
also be related to a number of biologic factors encompass-
ing genetic, immunologic (24,25), and anatomic cofactors. 
Hormonally mediated sex-based responses to inflammation 
have  been  postulated  as  a  pathophysiologic  mechanism 
(23,26) for pulmonary NTM disease. Even among persons 
with cystic fibrosis, who have a well characterized genetic 
predisposition to pulmonary NTM disease, sex differences 
exist (23,27). Finally, a predisposing morphotype of tall, 
thin white women with underlying illnesses of mitral valve 
prolapse, scoliosis, and pectus excavatum suggests genetic 
components to the phenotype (5,28).
The  overlap  between  bronchiectasis  and  pulmonary 
NTM is extensive but of unclear etiology. Like pulmo-
nary NTM, bronchiectasis is thought to be a common final 
manifestation  of  several  conditions,  including  infectious 
causes as triggers of inflammation (22). Current estimates 
of bronchiectasis are limited, but a recent analysis of a na-
tionally representative nonhospitalized population estimat-
ed a prevalence of 272/100,000 persons >75 years of age 
in 2001; age and sex distribution was strikingly similar to 
that for pulmonary NTM (29). How much of bronchiectasis 
represents undiagnosed NTM-associated disease is unclear. 
Among persons >65 years of age in the United States, 26% 
of patients with chronic heart failure also had COPD and 
bronchiectasis,  and  these  conditions  posed  an  increased 
risk for hospitalization (30).
The regional differences in prevalence and trends of 
pulmonary NTM hospitalizations are intriguing. Mycobac-
terium avium complex, the most common group of NTM 
causing infection in humans, can be acquired through ex-
posure to either soil or water. Whether these geographic 
differences in prevalence are caused by differential expo-
sure to NTM in certain regions related to human activity 
or to increased concentrations of mycobacteria in certain 
environments, or both, is not clear. Heterogeneity in geo-
graphic prevalence of disease, NTM isolation, and myco-
bacterial growth has been demonstrated previously; some 
of the highest disease and isolation prevalence are found 
in the southeastern United States, particularly along the 
coastal regions of the Atlantic and Gulf coasts. A higher 
prevalence of NTM exposures in these areas, based on skin 
hypersensitivity tests, was first demonstrated in surveys of 
Navy recruits using purified protein derivative B (M. intra-
cellulare) (19).
Subsequent surveys of NTM isolates on the basis of 
patient isolates referred to state public health laboratories 
found a greatly elevated prevalence of isolation in Florida 
(29/100,000 population), relative to California (1.7/100,000 
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Figure  4.  Age-adjusted  prevalence  of  non-AIDS  pulmonary 
nontuberculous mycobacteria–associated hospitalizations among 
men,  California  (CA),  Florida  (FL),  and  New  York  (NY),  USA, 
Healthcare Cost and Utilization Project state inpatient databases, 
1998–2005.
Figure  5.  Age-adjusted  prevalence  of  non-AIDS  pulmonary 
nontuberculous mycobacteria–associated hospitalizations among 
women, California (CA), Florida (FL), and New York (NY), USA, 
Healthcare Cost and Utilization Project state inpatient databases, 
1998–2005.Nontuberculous Mycobacteria Lung Disease, USA
population) and New York (2.0/100,000 population) (31). 
More recently, a multisite study of pulmonary NTM prev-
alence  among  cystic  fibrosis  patients  found  the  highest 
prevalence primarily at sites in the southeastern and south-
western coastal areas (32). Higher average temperature and 
humidity in these areas could favor mycobacterial growth 
or survival in aerosol droplets. NTM have been isolated and 
identified in drinking water systems throughout the United 
States,  including  those  with  a  variety  of  water  sources 
(surface/groundwater),  water  types  (hard/soft;  high/low 
organic), and disinfectants used (chlorine/ozone) (33,34). 
The acidic, brown water swamps in the southeastern United 
States, particularly along the coastal region of the Atlantic 
and Gulf shores, harbor high numbers of NTM. DNA fin-
gerprinting techniques applied to NTM isolates have shown 
the identical pattern among isolates obtained from patients 
and their drinking water supply (35,36). Many NTM spe-
cies have high innate chlorine and biocide resistance, and 
therefore treatment of municipal water systems with these 
disinfecting agents may shift the bacterial population to-
wards mycobacteria. Furthermore, some of these species 
can persist in flowing water distribution systems through 
their creation of biofilms (37).
This study had several limitations. First, these data 
represent  a  hospitalized  population;  most  pulmonary 
NTM diseases are diagnosed and managed in the outpa-
tient setting. Prevalence trends are likely to be different in 
outpatient populations, depending on the factors influenc-
ing hospitalization. Because persons may be more likely 
to be hospitalized later in the course of the disease, our 
data could therefore be skewed toward an older popula-
tion. In a recent case-series of nonhospitalized patients 
(95% women), the average age at diagnosis was 56 years 
(5). In our study, women >70 years of age predominated. 
However, until we have better data on outpatients, we 
cannot definitively know the nature and direction of this 
bias. Although the populations of some states included in 
this analysis may have a higher proportion of elderly per-
sons, we accounted for this by estimating age-adjusted or 
age-specific prevalence.
We cannot know from these data whether the trends 
in Florida are due to immigration of retirees from other 
areas, however, geographic differences in exposure have 
been noted among young Navy recruits who were lifelong 
residents in their states (19). Thus, these differences are un-
likely to be explained solely by migration. Awareness of 
NTM disease may have increased in recent years because 
of the discovery of new species. Whether this discovery has 
led to more testing and more frequent diagnosis of NTM 
along with increased use of commercial molecular probes 
for the most common species, is uncertain. Also, it is un-
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Table 3. Secondary diagnoses in hospitalizations in which non-
AIDS pulmonary NTM is the primary diagnosis, HCUP-SID, USA, 
1998–2005*
Secondary diagnosis  Total no. 
% Pulmonary NTM as 
primary diagnosis 








Hemoptysis  438 8.5




Esophageal reflux  295 5.7
Acute respiratory failure  184 3.6
*NTM, nontuberculous mycobacteria; HCUP, Healthcare Cost and 
Utilization Project; SID, state inpatient databases; COPD, chronic 
obstructive pulmonary disease. 
Figure  6.  Prevalence  of  chronic  obstructive  pulmonary  disease 
as a secondary diagnosis by age group and sex when non-AIDS 
pulmonary nontuberculous mycobacteria is the primary diagnosis, 
Healthcare Cost and Utilization Project state inpatient databases, 
USA, 1998–2005.
Figure 7. Prevalence of bronchiectasis as a secondary diagnosis 
by age group and sex when non-AIDS pulmonary nontuberculous 
mycobacteria  is  the  primary  diagnosis,  Healthcare  Cost  and 
Utilization Project state inpatient databases, USA, 1998–2005.RESEARCH
clear as to whether use of these probes would vary greatly 
by geographic area. Another limitation is that the validity of 
the ICD-9-CM codes for NTM is unknown. Because pul-
monary NTM is a relatively rare condition, hospitalizations 
identified by use of these codes likely represent an underes-
timate of the impact of pulmonary NTM. Because we could 
not identify multiple hospitalizations for any 1 patient, any 
given patient could be represented more than once in a giv-
en year. However, considering the rarity of this disease it is 
unlikely that this issue would result in a substantial overes-
timate of the true impact of pulmonary NTM.
In summary, pulmonary NTM represents an increas-
ing cause of illness in the United States, particularly among 
women in selected areas. Further research is needed to de-
fine the prevalence of disease in nonhospitalized persons in 
regions throughout the United States and to elucidate risk 
factors for disease susceptibility as well as environmental 
exposure. 
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